Wednesday, July 22, 2026 The CCTG MA.39 Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer has successfully reached the sample size of 2140 participants and is now closed to further accrual.The study is accessing the need for regional radiotherapy after breast surgery and the ability of biomarkers to predict the risk of local recurrence and the effectiveness of radiation. The results will determine if regional radiotherapy can be safely omitted in women with 1-3 positive axillary lymph nodes and luminal A subtype. Although regional radiation therapy is part of standard treatment, recent research suggests that receiving no regional radiation may work just as well in some low-risk types of breast cancer. The benefits of not receiving regional radiation therapy may include less fewer clinic visits and side effects, better quality of life, and less cost over time for the healthcare system.Dr. Tim Whelan from Juravinski Cancer Centre at London Health Sciences is the MA 39 study chair, he led a network of investigators across Canada and in the US and trained a number of radiation oncologists interested in the optimal treatment of women with breast cancer.
